HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on UroGen Pharma and increased the price target from $60 to $64, indicating positive sentiment towards the company's stock.
October 16, 2024 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on UroGen Pharma and increased the price target from $60 to $64, suggesting a positive outlook for the stock.
The increase in price target from $60 to $64 by HC Wainwright & Co. reflects a positive sentiment and confidence in UroGen Pharma's future performance. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100